Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6909-6922

  Lai, Jing ^a   Nie, Weiwei ^a   Zhang, Wenwen ^b   Wang, Yucai ^c   Xie, Ruilian ^a   Wang, Yanru ^a   Gu, Jun ^b   Xu, Jing ^b   Song, Wei ^a   Yang, Fang ^b   Huang, Guichun ^b   Cao, Peng ^d   Guan, Xiaoxiang ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d Jiangsu Province Hospital of Chinese Medicine   (China)

Author keywords

Breast cancer; Methylation; Nrf 2; TAp73; Transcription; Np73

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN P73; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR NRF2; DNA BINDING PROTEIN; NFE2L2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER TISSUE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYROSEQUENCING; S PHASE CELL CYCLE CHECKPOINT; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; C57BL MOUSE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KNOCKOUT MOUSE; MCF 7 CELL LINE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84907080728     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2230     Document Type: Article

References (40)

1. Melino G, De Laurenzi V and Vousden KH. p73: Friend or foe in tumorigenesis. Nature reviews Cancer. 2002; 2(8):605-615.
2. Melino G, Lu X, Gasco M, Crook T and Knight RA. Functional regulation of p73 and p63: development and cancer. Trends in biochemical sciences. 2003; 28(12):663-670.
3. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M and Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. The Journal of experimental medicine. 1998; 188(9):1763-1768.
4. Jost CA, Marin MC and Kaelin WG, Jr. p73 is a human p53-related protein that can induce apoptosis. Nature. 1997; 389(6647):191-194.
5. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G and Krammer PH. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell death and differentiation. 2005; 12(12):1564-1577.
6. Stiewe T, Zimmermann S, Frilling A, Esche H and Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer research. 2002; 62(13):3598-3602.
7. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR and Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000; 289(5477):304-306.
8. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & development. 2008; 22(19):2677-2691.
9. Belloni L, Moretti F, Merlo P, Damalas A, Costanzo A, Blandino G and Levrero M. DNp73alpha protects myogenic cells from apoptosis. Oncogene. 2006; 25(25):3606-3612.
10. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E and Moll UM. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. The Journal of experimental medicine. 2002; 196(6):765-780.
11. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T and Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer research. 2002; 62(3):636-641.
12. Putzer BM, Tuve S, Tannapfel A and Stiewe T. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript. Cell death and differentiation. 2003; 10(5):612-614.
13. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ, Agostini M, Bernardini S, Knight RA, Mak TW and Melino G. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci U S A. 2010; 107(29):12877-12882.
14. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K and Yasumoto K. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(20):6905-6911.
15. Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, Kitamura Y, Ohara N, Ouchida M, Ohshima K, Shimizu K, Tanimoto M, et al. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol. 2010; 176(1):402-415.
16. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG and Carraway HE. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics: official journal of the DNA Methylation Society. 2010; 5(7):590-600.
17. Daskalos A, Logotheti S, Markopoulou S, Xinarianos G, Gosney JR, Kastania AN, Zoumpourlis V, Field JK and Liloglou T. Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer. Cancer letters. 2011; 300(1):79-86.
18. Ushiku T, Chong JM, Uozaki H, Hino R, Chang MS, Sudo M, Rani BR, Sakuma K, Nagai H and Fukayama M. p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. International journal of cancer Journal international du cancer. 2007; 120(1):60-66.
19. Liu SS, Leung RC, Chan KY, Chiu PM, Cheung AN, Tam KF, Ng TY, Wong LC and Ngan HY. p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(10):3309-3316.
20. Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nature reviews Genetics. 2002; 3(6):415-428.
21. Robertson KD. DNA methylation and human disease. Nature reviews Genetics. 2005; 6(8):597-610.
22. Lantry LE, Zhang Z, Crist KA, Wang Y, Kelloff GJ, Lubet RA and You M. 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis. 1999; 20(2):343-346.
23. Gore SD. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol. 2005; 2 Suppl 1:S30-35.
24. Banelli B, Casciano I and Romani M. Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000; 19(39):4553-4556.
25. Casciano I, Banelli B, Croce M, Allemanni G, Ferrini S, Tonini GP, Ponzoni M and Romani M. Role of methylation in the control of DeltaNp73 expression in neuroblastoma. Cell death and differentiation. 2002; 9(3):343-345.
26. Seelan RS, Irwin M, van der Stoop P, Qian C, Kaelin WG, Jr. and Liu W. The human p73 promoter: characterization and identification of functional E2F binding sites. Neoplasia. 2002; 4(3):195-203.
27. Stiewe T and Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nature genetics. 2000; 26(4):464-469.
28. Tosi GM, Trimarchi C, Macaluso M, La Sala D, Ciccodicola A, Lazzi S, Massaro-Giordano M, Caporossi A, Giordano A and Cinti C. Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach. Oncogene. 2005; 24(38):5827-5836.
29. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G and Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001; 8(12):1213-1223.
30. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C and Otterson GA. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene. 2001; 20(53):7787-7796.
31. Al-Salihi M, Yu M, Burnett DM, Alexander A, Samlowski WE and Fitzpatrick FA. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics: official journal of the DNA Methylation Society. 2011; 6(8):1021-1028.
32. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J and Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103(5):1635-1640.
33. Logotheti S, Michalopoulos I, Sideridou M, Daskalos A, Kossida S, Spandidos DA, Field JK, Vojtesek B, Liloglou T, Gorgoulis V and Zoumpourlis V. Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer. The FEBS journal. 2010; 277(14):3014-3027.
34. Chen C and Kong AN. Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends in pharmacological sciences. 2005; 26(6):318-326.
35. Frohlich DA, McCabe MT, Arnold RS and Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 2008; 27(31):4353-4362.
36. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J and Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene. 2002; 21(31):4715-4727.
37. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T and Nakagawara A. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol. 2002; 22(8):2575-2585.
38. Nyman U, Sobczak-Pluta A, Vlachos P, Perlmann T, Zhivotovsky B and Joseph B. Full-length p73alpha represses drug-induced apoptosis in small cell lung carcinoma cells. J Biol Chem. 2005; 280(40):34159-34169.
39. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB and Chambers AF. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast cancer research: BCR. 2008; 10(4):R62.
40. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, Gorgoulis V, Field JK and Liloglou T. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. International journal of cancer Journal international du cancer. 2009; 124(1):81-87.